Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmasset starts HCV drug Phase 2b Atomic trial
Pharmasset will assess PSI-7977 400mg QD with pegylated interferon and ribavirin in patients with HCV genotype 1, 4, 5 or 6 who have not been treated previously. The
Pharmasset will assess PSI-7977 400mg QD with pegylated interferon and ribavirin in patients with HCV genotype 1, 4, 5 or 6 who have not been treated previously. The
The company has posted net loss of $7.74m, or $0.43 loss per diluted share, as compared to net loss of $9.15m, or $0.62 loss per diluted share, for
As per the agreement, Merck will give development license for its clinical-stage compounds Pruvanserin and Sarizotan to Newron and will hold buy back options for each of the
As per the terms of the agreement, GSK will transfer the ownership of penicillin manufacturing site in Bristol, Tennessee and the rights of Augmentin and Amoxil brands in
Motesanib is an investigational, orally-administered small molecule antagonist of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptors, and stem cell factor receptor. The
The Phase 2 study is designed to compare MDV3100 with bicalutamide – a commonly used anti-androgen, and is expected to enroll approximately 370 patients in North America and
In the first of a two segment Phase 2a trial, 64 patients were enrolled and randomised to receive three doses of ACH-1625 given once daily (200mg, 400mg or
The registration dossier of Montelukast Sodium OSF will be primarily based on pharmacokinetic studies, without the need for clinical efficacy trials. The company claims that Montelukast Sodium OSF
Amgen claims that Vectibix, in conjuction with chemotherapy, offers an an important treatment option for patients with wild-type KRAS mCRC. Accoding to the company, the results from the
BioClinica said the new EDA will collect planning information from all of Millennium’s Optimizer-simulated protocols in a central repository and provide an enterprise-wide view of the demand over